$NORD
Nordicus Partners Corp

2023 Q4 Form 10-Q Financial Statement

#000149315223040448 Filed on November 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $74.99K $96.88K
YoY Change -91.21%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $74.99K $96.88K $47.00K
YoY Change -91.21% 106.13% -68.03%
Operating Profit -$74.99K -$96.88K -$47.00K
YoY Change -91.21% 106.13% -68.03%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$1.909K
YoY Change
Pretax Income -$74.99K -$98.79K -$47.00K
YoY Change -91.19% 110.19% -68.03%
Income Tax
% Of Pretax Income
Net Earnings -$74.99K -$98.79K -$47.00K
YoY Change -91.19% 110.19% -68.03%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01 -$0.01 -$0.01
Diluted Earnings Per Share -$0.01 -$0.01 -$8.273K
COMMON SHARES
Basic Shares Outstanding 10.88M shares 10.80M shares 5.681M shares
Diluted Shares Outstanding 10.88M shares 10.85M shares 5.681M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $38.79K $10.77K $1.000K
YoY Change 675.8% 977.0% -66.67%
Cash & Equivalents $38.79K $10.77K $1.000K
Short-Term Investments
Other Short-Term Assets $0.00 $0.00 $9.000K
YoY Change -100.0% -100.0%
Inventory
Prepaid Expenses $9.000K
Receivables
Other Receivables
Total Short-Term Assets $38.79K $10.77K $10.00K
YoY Change 546.47% 7.72% 233.33%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $1.750M $1.750M
YoY Change
Other Assets $8.774K $5.327K
YoY Change
Total Long-Term Assets $1.759M $1.755M $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $38.79K $10.77K $10.00K
Total Long-Term Assets $1.759M $1.755M $0.00
Total Assets $1.798M $1.766M $10.00K
YoY Change 29859.37% 17560.99% 233.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $37.45K $9.880K $22.00K
YoY Change -55.09% -80.87%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $62.97K $25.69K $28.00K
YoY Change 25.94% -8.24% -75.65%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $62.97K $25.69K $28.00K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $62.97K $25.69K $28.00K
YoY Change 25.94% -8.24% -75.65%
SHAREHOLDERS EQUITY
Retained Earnings -$42.41M -$42.34M -$38.81M
YoY Change 6.94% 9.1%
Common Stock $10.98K $10.88K $6.000K
YoY Change 82.93% 81.27%
Preferred Stock
YoY Change
Treasury Stock (at cost) $30.33K $30.33K $30.00K
YoY Change 1.09% 1.09%
Treasury Stock Shares 1.534K shares
Shareholders Equity $1.735M $1.740M -$18.00K
YoY Change
Total Liabilities & Shareholders Equity $1.798M $1.766M $10.00K
YoY Change 29859.37% 17560.99% 233.33%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$74.99K -$98.79K -$47.00K
YoY Change -91.19% 110.19% -68.03%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$50.86K -$100.1K -$44.00K
YoY Change 41.28% 127.48% -4.35%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 83.94K 81.92K -141.0K
YoY Change 109.85% -158.1%
NET CHANGE
Cash From Operating Activities -50.86K -100.1K -44.00K
Cash From Investing Activities
Cash From Financing Activities 83.94K 81.92K -141.0K
Net Change In Cash 33.08K -18.17K -185.0K
YoY Change 727.0% -90.18% 302.17%
FREE CASH FLOW
Cash From Operating Activities -$50.86K -$100.1K -$44.00K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--03-31
dei Entity Central Index Key
EntityCentralIndexKey
0001011060
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q1 NORD Common Stock To Be Issued
CommonStockToBeIssued
usd
CY2022Q3 us-gaap Officers Compensation
OfficersCompensation
usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
usd
us-gaap Share Based Compensation
ShareBasedCompensation
usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
usd
us-gaap Share Based Compensation
ShareBasedCompensation
usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
usd
us-gaap Payments Of Capital Distribution
PaymentsOfCapitalDistribution
usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
us-gaap Stock Issued1
StockIssued1
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-11737
dei Entity Registrant Name
EntityRegistrantName
NORDICUS PARTNERS CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3186647
dei Entity Address Address Line1
EntityAddressAddressLine1
3651 Lindell Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite D565
dei Entity Address City Or Town
EntityAddressCityOrTown
Las Vegas
dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89103
dei City Area Code
CityAreaCode
(424)
dei Local Phone Number
LocalPhoneNumber
256-8560
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10876248 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10772 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7149 usd
CY2023Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
44481 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
770 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
10772 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
52400 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5327 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2625 usd
CY2023Q3 us-gaap Long Term Investments
LongTermInvestments
1750000 usd
CY2023Q3 us-gaap Assets
Assets
1766099 usd
CY2023Q1 us-gaap Assets
Assets
55025 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
9882 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1354 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
25692 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
27367 usd
CY2023Q3 us-gaap Liabilities
Liabilities
25692 usd
CY2023Q1 us-gaap Liabilities
Liabilities
27367 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-52357 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-148470 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5087491 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10876248 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8296248 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
10876 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
8296 usd
CY2023Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
1534 shares
CY2023Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
1534 shares
CY2023Q3 us-gaap Treasury Stock Value
TreasuryStockValue
30328 usd
CY2023Q1 us-gaap Treasury Stock Value
TreasuryStockValue
30328 usd
CY2023Q3 NORD Common Stock To Be Issued
CommonStockToBeIssued
25000 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
44074108 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
42246688 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2500 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
665 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-42336749 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-42197663 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1740407 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
27658 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1766099 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55025 usd
CY2023Q3 us-gaap Officers Compensation
OfficersCompensation
30593 usd
us-gaap Officers Compensation
OfficersCompensation
57593 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5009771 usd
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
56868 usd
CY2022Q3 us-gaap Professional Fees
ProfessionalFees
10847 usd
us-gaap Professional Fees
ProfessionalFees
76793 usd
us-gaap Professional Fees
ProfessionalFees
19851 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9420 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
41510 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14084 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
57869 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
96881 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
52357 usd
us-gaap Operating Expenses
OperatingExpenses
148470 usd
us-gaap Operating Expenses
OperatingExpenses
5087491 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-96881 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1909 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5685 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9384 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5685 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1909 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5685 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9384 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5685 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-98790 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-46672 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-139086 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5081806 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-98790 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-46672 usd
us-gaap Net Income Loss
NetIncomeLoss
-139086 usd
us-gaap Net Income Loss
NetIncomeLoss
-5081806 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3104 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3165 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-101894 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46672 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-142251 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5081806 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.89
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.89
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10846628 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10846628 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5681248 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5681248 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9722814 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9722814 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5681248 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5681248 shares
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
27658 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1750000 usd
CY2023Q2 NORD Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
25000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40357 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1762301 usd
CY2023Q3 NORD Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
80000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-101894 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1740407 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
194511 usd
CY2022Q2 NORD Adjustments To Additional Paid In Capital Stockbased Compensation Fair Value Of Warrants
AdjustmentsToAdditionalPaidInCapitalStockbasedCompensationFairValueOfWarrants
5009771 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5035134 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
169148 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46672 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
122476 usd
us-gaap Net Income Loss
NetIncomeLoss
-139086 usd
us-gaap Net Income Loss
NetIncomeLoss
-5081806 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5009771 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1932 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5185 usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-44481 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-12127 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-6574 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
8528 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-19998 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-100136 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-103792 usd
us-gaap Payments Of Capital Distribution
PaymentsOfCapitalDistribution
141350 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1924 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
105000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
106924 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-141350 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
6788 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-245142 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-3165 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
7149 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
245945 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10772 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
803 usd
us-gaap Stock Issued1
StockIssued1
1750000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_841_eus-gaap--UseOfEstimates_zCEu28UsRZfg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_863_z2ukYjzIikK3">Use of Estimates</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Company’s accounting estimates include the collectability of receivables, useful lives of long-lived assets and recoverability of those assets, impairment in fair value of goodwill.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_849_eus-gaap--ConcentrationRiskCreditRisk_zWVLtX8RMZv2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_860_zy7dqwmPpyl6">Concentration of Credit Risk</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We maintain our cash in bank deposit accounts, the balances of which at times may exceed federally insured limits. We continually monitor our banking relationships and consequently have not experienced any losses in our accounts. We believe we are not exposed to any significant credit risk on cash.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6530000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5860000 shares
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-42336749 usd
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
NORD Preferred Stock Issued And Redeemed Shares
PreferredStockIssuedAndRedeemedShares
500000 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
825000 usd

Files In Submission

Name View Source Status
nord-20230930_cal.xml Edgar Link unprocessable
nord-20230930_def.xml Edgar Link unprocessable
0001493152-23-040448-index-headers.html Edgar Link pending
0001493152-23-040448-index.html Edgar Link pending
0001493152-23-040448.txt Edgar Link pending
0001493152-23-040448-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
nord-20230930.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
nord-20230930_lab.xml Edgar Link unprocessable
nord-20230930_pre.xml Edgar Link unprocessable